3-n-methylspiperone has been researched along with clozapine in 8 studies
| Studies (3-n-methylspiperone) | Trials (3-n-methylspiperone) | Recent Studies (post-2010) (3-n-methylspiperone) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
|---|---|---|---|---|---|
| 155 | 6 | 7 | 9,691 | 747 | 3,148 |
| Protein | Taxonomy | 3-n-methylspiperone (IC50) | clozapine (IC50) |
|---|---|---|---|
| Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
| D | Rattus norvegicus (Norway rat) | 1.066 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
| Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
| Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
| Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
| Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
| Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
| D | Bos taurus (cattle) | 4.09 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meltzer, HY; Stockmeier, CA | 1 |
| Coenen, HH; Hamacher, K; Heiss, WD; Herholz, K; Huber, M; Karbe, H; Lövenich, A; Stöcklin, G; Wienhard, K | 1 |
| Axelsson, S; Eckernäs, SA; Ekblom, B; Fasth, KJ; Gullberg, P; Hartvig, P; Långström, B; Lindström, L; Lundqvist, H | 1 |
| Farde, L; Halldin, C; Karlsson, P; Nordström, AL; Nyberg, S; Sedvall, G | 1 |
| Farde, L; Halldin, C; Nordström, AL | 1 |
| DiCarlo, JJ; Meltzer, HY; Stockmeier, CA; Thompson, P; Zhang, Y | 1 |
| Berridge, MS; Compton-Toth, BA; Goyer, PF; Meltzer, HY; Miraldi, F; Morris, ED; Schulz, SC; Semple, WE; Wong, DF | 1 |
| Armogida, M; Chiacchio, S; Colzi, A; Corsini, GU; DeMontis, MG; Maggio, R; Scarselli, M | 1 |
1 trial(s) available for 3-n-methylspiperone and clozapine
| Article | Year |
|---|---|
High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET.
Topics: Adult; Antipsychotic Agents; Clozapine; Dopamine Agonists; Female; Humans; Male; Middle Aged; Prefrontal Cortex; Psychotic Disorders; Raclopride; Receptors, Serotonin; Salicylamides; Schizophrenia; Spiperone; Tomography, Emission-Computed | 1993 |
7 other study(ies) available for 3-n-methylspiperone and clozapine
| Article | Year |
|---|---|
In vivo occupancy of dopamine receptors by antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Haloperidol; Humans; Rats; Receptors, Dopamine; Receptors, Serotonin; Spiperone | 1992 |
Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol.
Topics: Adult; Aged; Brain Chemistry; Clozapine; Female; Fluorine Radioisotopes; Glucose; Haloperidol; Humans; Male; Middle Aged; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Spiperone; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1991 |
Receptor binding and selectivity of three 11C-labelled dopamine receptor antagonists in the brain of rhesus monkeys studied with positron emission tomography.
Topics: Animals; Brain; Clozapine; Female; Macaca mulatta; Raclopride; Receptors, Dopamine; Salicylamides; Spiperone; Tissue Distribution; Tomography, Emission-Computed | 1988 |
D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.
Topics: Adult; Benzazepines; Brain; Clozapine; Female; Humans; Male; Middle Aged; Raclopride; Receptors, Dopamine; Receptors, Serotonin; Salicylamides; Schizophrenia; Spiperone; Tomography, Emission-Computed; Treatment Outcome | 1995 |
Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.
Topics: Animals; Antipsychotic Agents; Binding Sites; Clozapine; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Kinetics; Male; Mice; Olfactory Pathways; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Serotonin; Spiperone; Tritium | 1993 |
PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Bipolar Disorder; Carbon Radioisotopes; Case-Control Studies; Cerebral Cortex; Clozapine; Dopamine Agonists; Female; Humans; Male; Receptors, Dopamine D2; Receptors, Serotonin; Schizophrenia; Spiperone; Tomography, Emission-Computed | 1996 |
Reconstitution of functional dopamine D(2s) receptor by co-expression of amino- and carboxyl-terminal receptor fragments.
Topics: Animals; Apomorphine; Binding, Competitive; Clozapine; Colforsin; COS Cells; Cyclic AMP; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Membranes; Peptide Fragments; Pergolide; Quinpirole; Radioligand Assay; Rats; Receptors, Dopamine D2; Recombinant Fusion Proteins; Spiperone; Transfection; Tritium | 2000 |